Tadeusz Robak

Summary

Affiliation: University of Lodz
Country: Poland

Publications

  1. ncbi request reprint Langerhans cell histiocytosis in a patient with systemic lupus erythematosus: a clonal disease responding to treatment with cladribine, and cyclophosphamide
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 513 Lodz, ul Pabianicka 62 st, Poland
    Leuk Lymphoma 43:2041-6. 2002
  2. ncbi request reprint The search for optimal treatment in relapsed and refractory acute myeloid leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, Poland
    Leuk Lymphoma 43:281-91. 2002
  3. ncbi request reprint Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
    Drugs Aging 21:779-91. 2004
  4. ncbi request reprint Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1)
    Tadeusz Robak
    Department of Hematology, Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland
    Med Sci Monit 11:PI71-9. 2005
  5. ncbi request reprint Monoclonal antibodies in the treatment of chronic lymphoid leukemias
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 513 Lodz, ul Pabianicka 62, Poland
    Leuk Lymphoma 45:205-19. 2004
  6. ncbi request reprint Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine
    T Robak
    Department of Haematology, Medical University of Łódź and Copernicus Memorial Hospital, Pabianicka 62, 93 513, ul Pabianicka 62, Łódź, Poland
    Eur J Cancer 40:383-9. 2004
  7. ncbi request reprint Chronic myelomonocytic leukemia coexisting with B-cell chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Ltd, Copernicus Memorial Hospital, 93 513 Lódź ul Pabianicka 62, Poland
    Leuk Lymphoma 44:2001-8. 2003
  8. ncbi request reprint Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia
    J Gora-Tybor
    Department of Hematology Medical University of Lodz, Lodz, 93 513 Poland
    Neoplasma 49:145-8. 2002
  9. ncbi request reprint Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Pabianicka 62 str, 93 513 Lodz, Poland
    Ann Hematol 83:225-31. 2004
  10. ncbi request reprint Aggressive primary plasma cell leukemia with skin manifestations, trisomy 8 and molecular oligoclonal features
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Poland
    Leuk Lymphoma 43:1067-73. 2002

Detail Information

Publications147 found, 100 shown here

  1. ncbi request reprint Langerhans cell histiocytosis in a patient with systemic lupus erythematosus: a clonal disease responding to treatment with cladribine, and cyclophosphamide
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 513 Lodz, ul Pabianicka 62 st, Poland
    Leuk Lymphoma 43:2041-6. 2002
    ..The disease was refractory to treatment with high doses of prednisone and vincristine but complete response was achieved after treatment with caldribine combined with cyclophosphamide...
  2. ncbi request reprint The search for optimal treatment in relapsed and refractory acute myeloid leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, Poland
    Leuk Lymphoma 43:281-91. 2002
    ..New cytotoxic drugs, agents with novel mechanisms of action, and new treatment strategies are currently being investigated. The management of refractory or relapsed AML patients is reviewed in this study...
  3. ncbi request reprint Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
    Drugs Aging 21:779-91. 2004
    ..New therapeutic approaches are necessary to improve the outcome in this age group of patients with ALL...
  4. ncbi request reprint Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1)
    Tadeusz Robak
    Department of Hematology, Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland
    Med Sci Monit 11:PI71-9. 2005
    ..Here we present the final report of this study...
  5. ncbi request reprint Monoclonal antibodies in the treatment of chronic lymphoid leukemias
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 513 Lodz, ul Pabianicka 62, Poland
    Leuk Lymphoma 45:205-19. 2004
    ..The presented results indicate that these agents are highly active and well tolerated even if the patients were resistant to 2-CdA or DCF...
  6. ncbi request reprint Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine
    T Robak
    Department of Haematology, Medical University of Łódź and Copernicus Memorial Hospital, Pabianicka 62, 93 513, ul Pabianicka 62, Łódź, Poland
    Eur J Cancer 40:383-9. 2004
    ..However, further studies are necessary to establish the real risk of lung cancer in CLL patients treated with 2-CdA...
  7. ncbi request reprint Chronic myelomonocytic leukemia coexisting with B-cell chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Ltd, Copernicus Memorial Hospital, 93 513 Lódź ul Pabianicka 62, Poland
    Leuk Lymphoma 44:2001-8. 2003
    ..The patient died in January 2003, three months after diagnosis because of progression of both leukemias and associated pneumonia. Possible etiopathogenic relationship between both disorders is discussed...
  8. ncbi request reprint Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia
    J Gora-Tybor
    Department of Hematology Medical University of Lodz, Lodz, 93 513 Poland
    Neoplasma 49:145-8. 2002
    ..The level of these factors might correlate with the activity of the disease...
  9. ncbi request reprint Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Pabianicka 62 str, 93 513 Lodz, Poland
    Ann Hematol 83:225-31. 2004
    ..ALL of the elderly is a rare disease with poor prognosis. Further clinical trials evaluating the disease features, outcome, and new therapeutic approaches are warranted...
  10. ncbi request reprint Aggressive primary plasma cell leukemia with skin manifestations, trisomy 8 and molecular oligoclonal features
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Poland
    Leuk Lymphoma 43:1067-73. 2002
    ..He died 5 months after the diagnosis of PCL because of disease progression and pneumonia...
  11. ncbi request reprint Acute lymphoblastic leukemia in adult first manifested as severe aplastic anemia--role of molecular analysis in correct diagnosis
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Poland
    Leuk Lymphoma 43:1147-52. 2002
    ..We suggest that molecular analysis of monoclonality in patients with AA may be important for proper selection of the rare cases of ALL first presenting as marrow aplasia...
  12. ncbi request reprint Coexistence of chronic lymphocytic leukemia and essential thrombocythemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 513 Lodz, ul Pabianicka 62, Poland
    Leuk Lymphoma 44:1425-31. 2003
    ..Possible etiopathogenic relationships between both disorders and differential diagnosis of ET and reactive thrombocytosis (RT) are discussed...
  13. ncbi request reprint Efficacy and toxicity of low-dose melphalan in myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 513 Lodz, Poland
    Neoplasma 50:172-5. 2003
    ..5 and 4 months, p=0.003 and p=0.008, respectively). Low-dose melphalan shows significant activity in high-risk MDS and AML with multilineage dysplasia with acceptable toxicity...
  14. ncbi request reprint Hodgkin's type of Richter's syndrome in familial chronic lymphocytic leukemia treated with cladribine and cyclophosphamide
    Tadeusz Robak
    Department of Hematology, Medical University of Łódź, Pabianicka 62, 93 513 Łódź, Poland
    Leuk Lymphoma 44:859-66. 2003
    ..He is also the first published patient with familial CLL in whom this complication developed...
  15. ncbi request reprint Purine nucleoside analogues in the treatment of myleoid leukemias
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 513 Lodz, Pabianicka 62 Poland
    Leuk Lymphoma 44:391-409. 2003
    ..Finally, PNA, especially FA play an important role in non-myeloablative conditioning regimens for allogenic stem cell transplantation in high-risk patients, possibly also with myeloid malignancies...
  16. ncbi request reprint Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen--diagnostic and therapeutic dilemmas
    Tadeusz Robak
    Department of Haematology, Medical University of Lodz, 93 513 Lodz, ul Pabianicka 62, Poland
    Leuk Lymphoma 43:2343-50. 2002
    ..Finally, the patient received two courses of VAD vincristine, doxorubicin, dexamethasone) with further haematological improvement but complete response was not achieved...
  17. ncbi request reprint Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): an unusual variant of Richter's syndrome
    T Robak
    Department of Hematology and Department of Oncology, Medical University of Lodz, Poland
    Eur J Haematol 67:322-7. 2001
    ..Overall survival with current strategies is poor, and further insight into the natural history, biology, and treatment of PBL are needed...
  18. ncbi request reprint The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 513, Pabianicka 62 str, Lodz, Poland
    Ann Hematol 84:63-70. 2005
    ....
  19. ncbi request reprint Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 513 Lodz, Pabianicka 62 st, Poland
    Transfus Apher Sci 32:33-44. 2005
    ..A multicenter prospective randomized study comparing alemtuzumab and chlorambucil as first line therapies are ongoing and preliminary results show acceptable toxicity profile of monoclonal antibody...
  20. ncbi request reprint Efficacy and safety of Privigen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura
    T Robak
    Department of Hematology, Medical University of Lodz, 2, Ciolkowskiego str, Lodz 93 510, Poland
    Hematology 14:227-36. 2009
    ..Thus, in patients with chronic ITP, a two-day regimen of Privigen was effective in increasing platelet count, reducing bleeding events and was well tolerated...
  21. ncbi request reprint Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Poland
    Leuk Lymphoma 48:1092-101. 2007
    ..The results of our study show that the CMC regimen is effective salvage therapy with acceptable toxicity in heavily pretreated patients with NHL including MCL and DLBCL...
  22. ncbi request reprint [Progress and perspectives in the treatment of systemic lupus erythematosus]
    Ewa Robak
    Katedra i Klinika Dermatologii i Wenerologii, Uniwersytetu Medycznego w Lodzi
    Przegl Lek 62:894-9. 2005
    ..However, new therapeutic strategies must be tested according to the established principles of clinical trial methods...
  23. ncbi request reprint [Diagnostic problems and evaluation of disease activity in systemic lupus erythematosus]
    Ewa Robak
    Katedra i Klinika Dermatologii i Wenerologii Uniwersytet Medyczny w Lodzi
    Przegl Lek 62:299-305. 2005
    ..At present they are widely used in clinical practice. In this review currently accepted methods of SLE activity evaluation are presented...
  24. ncbi request reprint Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Łódź, Copernicus Memorial Hospital Poland
    Hematol J 3:244-50. 2002
    ..The efficacy of the regimen seems to be higher than observed earlier after treatment with 2-CdA alone. A randomized clinical trial is in progress in our institutions...
  25. ncbi request reprint Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab
    Ewa Robak
    Department of Dermatology, Medical University of Lodz, Lodz, Poland
    Leuk Lymphoma 46:909-14. 2005
    ..The development of MCC in our patient may suggest that this complication rarely observed in CLL patients may have a link with strongly immunosuppressive therapy with 2-CdA and rituximab...
  26. ncbi request reprint Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity
    E Robak
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, 93 513 Lodz, Pabianicka 62 st, Poland
    Eur Cytokine Netw 12:445-52. 2001
    ..252, p = 0.05). In conclusion, serum levels of the angiogenic factors HGF and VEGF may be relevant in SLE pathogenesis. Their concentrations seem to be markers of SLE activity...
  27. ncbi request reprint Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Pabianicka, Poland
    Hematology 9:387-400. 2004
    ..In this review, epidemiology, biology, clinical characteristic and treatment approaches in RS and other secondary neoplasms in patients with CLL are discussed...
  28. ncbi request reprint Circulating endothelial cell kinetics and their potential predictive value during mobilization procedure
    Anna Szmigielska-Kapłon
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    J Clin Apher 28:341-8. 2013
    ..The aim of this study was to evaluate the numbers of CECs and their subsets during mobilization of hematopoietic stem cells...
  29. ncbi request reprint Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, 93 513 Lodz, Poland
    Blood 109:3672-5. 2007
    ..4%; 95% CI -4.3% to 7.0%; P = .64). In conclusion, HCL treatment with weekly 2-CdA infusions is equally effective but no safer than the standard 5-day 2-CdA protocol...
  30. doi request reprint Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status
    Jacek Treliński
    Department of Hematology, Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland
    Leuk Lymphoma 51:1727-33. 2010
    ..Our data suggest that VEGF levels are particularly elevated in patients with high leukocytosis. Further investigation should be undertaken to determine the possible role of antiangiogenic therapy in ET...
  31. ncbi request reprint Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers
    Jacek Treliński
    Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Ciolkowskiego 2, 93 510, Lodz, Poland
    Int J Hematol 91:792-8. 2010
    ..We confirmed the coagulation activation in ET and PV patients but found no differences in levels of coagulation activation markers in relation to JAK2-V617F mutational status...
  32. doi request reprint Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 510 Lodz, ul Ciołkowskiego 2, Poland
    J Clin Oncol 28:1863-9. 2010
    ..Both combinations have unsatisfactory activity in patients with 17p13 (TP53 gene) deletion...
  33. doi request reprint R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis
    Małgorzata Rogalińska
    Department of Cytobiochemisty, University of Lodz, Lodz, Poland
    J Cell Biochem 109:217-35. 2010
    ..Marked between-patient differences in expression patterns of apoptosis-regulating factors in CLL cells were observed, explaining the variations in patients' sensitivity to therapy...
  34. pmc Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases
    Małgorzata Rogalińska
    Department of Cytobiochemistry, University of Lodz, Lodz, Poland
    Cancer Biol Ther 14:6-12. 2013
    ..39) as compared with untreated cells. These results were confirmed by distinct cell viability, protein expression as well as by differences in calorimetry profiles...
  35. ncbi request reprint Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells
    Paweł Robak
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    Leuk Lymphoma 47:2625-34. 2006
    ..The SDX-101 plus ALT combination resulted in only sub-additive cytotoxicity (CI = 1.25). In conclusion, these data obtained in vitro indicate that addition of 2-CdA, FA or RIT to SDX-101 significantly enhance cytotoxicity in B-CLL cells...
  36. ncbi request reprint Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem
    Agnieszka Wierzbowska
    Department of Hematology, Medical University, Lodz, Poland
    Eur J Haematol 80:115-26. 2008
    ..In the current report, we present the final results of multi-center phase II study evaluating the efficacy and toxicity of CLAG-M salvage regimen in poor risk refractory/relapsed AML patients...
  37. doi request reprint The kinetics and apoptotic profile of circulating endothelial cells in autologous hematopoietic stem cell transplantation in patients with lymphoproliferative disorders
    Anna Szmigielska-Kaplon
    Department of Hematology, Medical University of Lodz, Ciolkowskiego 2, 93 513, Lodz, Poland
    Ann Hematol 92:1255-62. 2013
    ..CEC numbers significantly change during autologous HSCT. Our results suggest that progenitor CECs and CECs derived from microvessels both take part in successful engraftment...
  38. doi request reprint Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group
    Ewa Kalinka-Warzocha
    Department of Proliferative Diseases, Regional Oncology Center, Lodz, Poland
    Cancer 113:367-75. 2008
    ....
  39. ncbi request reprint Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment
    Tadeusz Robak
    Department of Hematology, Medical University of Łódź, Poland
    Eur J Haematol 69:27-36. 2002
    ..However, since the second response is usually shorter and myelotoxicity more pronounced than during the first therapy, more clinical trials to find other therapeutical approaches are necessary...
  40. ncbi request reprint Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients
    Agnieszka Wierzbowska
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, ul Pabianicka 62, 93 513, Lodz, Poland
    Ann Hematol 87:97-106. 2008
    ..The evaluation of CEC kinetics and apoptotic profile may be a promising tool to select AML patients with poor response to chemotherapy who may benefit from antiangiogenic therapies...
  41. doi request reprint CD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: evidence from two case-control studies in Polish Caucasians
    Krzysztof Jamroziak
    Department of Hematology, Medical University of Lodz, Ciolkowskiego 2, 93 513 Lodz, Poland
    Cancer Epidemiol Biomarkers Prev 18:945-53. 2009
    ..05 for all comparisons). In conclusion, our data show that CD38 SNPs may affect CD38 expression and contribute to the increased risk of B-CLL carcinogenesis...
  42. ncbi request reprint Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 513 Lodz, Pabianicka 62, Poland
    Leuk Lymphoma 45:937-44. 2004
    ..This regimen can be considered as an alternative treatment of CD-20 positive indolent lymphoproliferative disorders...
  43. ncbi request reprint Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Poland
    Blood 108:473-9. 2006
    ..No important differences in efficacy and toxicity were found between CC and 2-CdA regimens...
  44. doi request reprint Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma
    Krzysztof Jamroziak
    Department of Hematology, Medical University of Lodz, Ciolkowskiego 2, 93 513 Lodz, Poland
    Leuk Res 33:332-5. 2009
    ..Moreover, patient and control groups did not differ regarding MDR1 haplotype distribution (p=0.18). In conclusion, our results do not support major influence of MDR1 variants on the risk of myeloma in Caucasians...
  45. doi request reprint Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia
    Joanna Gora-Tybor
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    Leuk Lymphoma 50:62-7. 2009
    ..In conclusion, the number of CECs is increased in CLL and correlates with stage of the disease, but does not seem to directly reflect the intensity of neovascularisaton in the bone marrow...
  46. ncbi request reprint Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia
    Krzysztof Jamroziak
    Department of Haematology, Medical University of Łódź, Ciołkowskiego 2, PL 93 510 Łódź, Poland
    Pharmacol Rep 57:882-8. 2005
    ..Our results suggest that C3435T polymorphism in MDR1 gene is not a major prognosticator in adult ALL...
  47. ncbi request reprint MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia
    Krzysztof Jamroziak
    Department of Hematology, Medical University of Łódź, Ciołkowskiego 2, PL 93 510 Łódź, Poland
    Pharmacol Rep 58:720-8. 2006
    ..The differences in P-gp activity in B-CLL tumor cells related to MDR1 genotype may have implications to the response to chemotherapy with P-gp transported anticancer agents...
  48. ncbi request reprint Multiple myeloma in a patient with systemic lupus erythematosus, myasthenia gravis and non-familial diffuse palmoplantar keratoderma
    Halina Urbanska-Rys
    Department of Haematology, Medical University of Łódź, Copernicus Memorial Hospital, 93 513 Łódź Pabianicka st 62, Poland
    Leuk Lymphoma 45:1913-8. 2004
    ..Now the malignancy is in partial remission after CHOP therapy and the skin lesions have returned to their initial status. To our knowledge, this is the first case to be reported with coexistence of these four diseases...
  49. ncbi request reprint Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine
    Agnieszka Janus
    Departments of aHematology bExperimental Hematology, Medical University of Lodz, Poland
    Anticancer Drugs 20:693-701. 2009
    ..On the basis of these results, attempts to combine classical induction chemotherapy with an inhibitor of the mTOR kinase in AML treatment could be warranted...
  50. ncbi request reprint Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia
    Krzysztof Jamroziak
    Department of Haematology, Medical University of Lodz, ul Pabianicka 62, 93 513 Lodz, Poland
    Eur J Haematol 72:314-21. 2004
    ..Carriers of the TT genotype are more at risk of developing ALL than other individuals, whereas CC genotype carriers are supposed to have worse prognosis...
  51. ncbi request reprint In vitro cytotoxicity of ranpirnase (onconase) in combination with components of R-CHOP regimen against diffuse large B cell lymphoma (DLBCL) cell line
    Agata Majchrzak
    Department of Experimental Hematology, Medical University of Lodz, Poland
    Postepy Hig Med Dosw (Online) 67:1166-72. 2013
    ..In conclusion, these data indicate that further preclinical and eventually clinical studies assessing activity of ONC+R-CHOP treatment are warranted. ..
  52. doi request reprint Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials
    Jerzy Z Blonski
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    Eur J Haematol 91:1-9. 2013
    ..The relationship between treatments of chronic lymphocytic leukemia (CLL) with cladribine (2-CdA) or chlorambucil and immune thrombocytopenia (IT) has not been yet determined...
  53. doi request reprint Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results
    Ida Franiak-Pietryga
    Laboratory of Clinical and Transplant Immunology and Genetics, Copernicus Memorial Hospital, Lodz, Poland
    Leuk Res 36:1134-40. 2012
    ..Our results suggest that RCC drugs may act through influence on the expression of some apoptosis-involved genes dependently on the IGVH mutational status...
  54. ncbi request reprint Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms
    Ewa Robak
    Department of Dermatology, Medical University of Lodz, Lodz, Poland
    Clin Rheumatol 25:225-33. 2006
    ..This finding may reflect pathogenetic events during development of the disease, which include a persistent signal derived from circulating apoptotic lymphocytes, mobilizing the complement system, and attracting peripheral blood DC...
  55. doi request reprint The effect of repeated exposures to low-dose UV radiation on the apoptosis of peripheral blood mononuclear cells
    Joanna Narbutt
    Department of Dermatology, Medical University of Lodz, Lodz, Poland
    Arch Dermatol 145:133-8. 2009
    ..To investigate whether repeated exposures to low-dose UV or solar-simulated radiation induce apoptosis of peripheral blood mononuclear cells...
  56. ncbi request reprint No influence of 3435C>T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells
    Krzysztof Jamroziak
    Department of Hematology, Medical University of Lodz, Poland
    Ther Drug Monit 28:707-11. 2006
    ..The authors conclude that isolated 3435C>T ABCB1 SNP is not a major factor of the genetic susceptibility to adult AML, and that genotyping of this polymorphism does not allow predicting P-gp expression or activity in AML cells...
  57. doi request reprint Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    Cancer 115:94-100. 2009
    ..The results of this study have demonstrated that the cladribine and cyclophosphamide regimen may improve treatment results in this poor-risk patient population...
  58. ncbi request reprint Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    Cancer 107:1542-50. 2006
    ..In vitro studies have shown synergistic or additive interactions between rituximab and purine nucleoside analogues. The results of recent clinical trials seem to confirm these preclinical observations...
  59. doi request reprint Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide
    Jolanta D Zolnierczyk
    Department of Cytobiochemistry, University of Łódź, Łódź, Poland
    Ann N Y Acad Sci 1171:124-31. 2009
    ..These results confirm the high efficacy of roscovitine against CLL cells...
  60. ncbi request reprint The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro
    Anna Korycka
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    Eur J Haematol 73:418-26. 2004
    ..However, further experimental studies on the usefulness of these combinations in the treatment of myeloid leukemia patients are warranted...
  61. ncbi request reprint The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro
    Anna Korycka
    Department of Haematology, Medical University of Lodz, Copernicus Memorial Hospital, 62 Pabianicka Str, 93 513 Lodz, Poland
    Leuk Lymphoma 44:1549-55. 2003
    ..However, further experimental and clinical studies concerning the usefulness of these combinations in the treatment of CML patients seem warranted...
  62. ncbi request reprint TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies
    Tadeusz Robak
    Medical University of Lodz, Copernicus Memorial Hospital, Department of Hematology, 93 510 Lodz, Ciołkowskiego 2, Poland
    Curr Opin Investig Drugs 10:1383-90. 2009
    ..1 mg/kg. TRU-016 is a promising therapeutic agent for patients with B-cell lymphoid malignancies, especially patients refractory to standard treatment...
  63. ncbi request reprint Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
    Eur J Haematol 79:107-13. 2007
    ....
  64. doi request reprint Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction
    Michał Plewka
    Department of Cardiology, Medical University, Łódź, Poland
    Am J Cardiol 104:1336-42. 2009
    ..02), and the E/E' ratio (17 +/- 7 vs 14 +/- 5; p = 0.03) in the BMSC group. In conclusion, intracoronary injection of unselected BMSCs in patients with STEMI improved both LV systolic and diastolic function at 6 months of follow-up...
  65. ncbi request reprint Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus
    Ewa Robak
    Department of Dermatology and Venerology, Medical University of Łódź, ul Krzemieniecka 5, 94 017 Łódź, Poland
    Eur Cytokine Netw 15:222-30. 2004
    ..377, P -/+ 0.024). In conclusion, the correlation between peripheral blood DC subsets and serum levels of IFN-alpha and IFN-gamma suggests a possible relationship between these cytokines in the pathogenesis of SLE...
  66. ncbi request reprint Circulating endothelial cells in patients with acute myeloid leukemia
    Agnieszka Wierzbowska
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    Eur J Haematol 75:492-7. 2005
    ..In addition we correlated the levels of CEC with disease status, known prognostic factors and response to treatment...
  67. ncbi request reprint Current treatment options in prolymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Poland
    Med Sci Monit 13:RA69-80. 2007
    ..In this review, current therapeutic strategies in PLL are presented...
  68. doi request reprint The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia
    Jacek Treliński
    Department of Hematology, Medical University of Lodz, Lodz, Poland
    Blood Coagul Fibrinolysis 20:646-51. 2009
    ..This is the first report showing enhanced platelet-leukocyte aggregate formation in low-risk essential thrombocythemia patients and the efficacy of ASA in its reduction...
  69. ncbi request reprint Richter's syndrome in the brain first manifested as an ischaemic stroke
    Tadeusz Robak
    Department of Hematology, Medical University of Łódź, Copernicus Memorial Hospital 93 513 łódź, ul Pabianicka 62, Poland
    Leuk Lymphoma 45:1261-7. 2004
    ..The patient was then treated with brain irradiation (2000 cGy) and complete remission as assessed by MRI was achieved. Significant neurological improvement was observed and no clinical progression was stated 3 months after radiotherapy...
  70. ncbi request reprint A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Po
    A Wrzesien-Kus
    Department of Hematology, Medical University of Lodz, ul Pabianicka 62, 93 513, Lodz, Poland
    Ann Hematol 84:557-64. 2005
    ..We conclude that CLAG-M regimen has significant antileukemia activity in refractory AML, which seems to be better than the activity of many other regimens. The toxicity of the treatment is acceptable...
  71. ncbi request reprint The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study
    A Wrzesien-Kus
    Department of Hematology, Medical University of Lodz, Poland
    Neoplasma 49:405-11. 2002
    ..The hematological toxicity of this treatment seems to be comparable with "3+7" regimen...
  72. ncbi request reprint Alemtuzumab in the treatment of chronic lymphocytic leukemia
    Tadeusz Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz 93 513, Poland
    BioDrugs 19:9-22. 2005
    ..Moreover, antiviral and antibacterial prophylaxis is mandatory...
  73. ncbi request reprint A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG)
    A Wrzesien-Kus
    Department of Hematology, Medical University, Łódź, Poland
    Eur J Haematol 71:155-62. 2003
    ....
  74. ncbi request reprint Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia
    T Robak
    Department of Hematology, Medical University, , Poland
    Leukemia 15:1510-6. 2001
    ..However, toxicity, especially after CMC5 administration, is significant. Therefore, we recommend the CMC3 but not the CMC5 programme for further evaluation...
  75. ncbi request reprint Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies
    T Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Poland
    Chemotherapy 51:247-51. 2005
    ..Seven out of 20 patients (35%) responded, including one complete response. Median overall survival time of responding patients was 22 months (range 3-30). Myelosuppression and infections were the major toxicity of the EC regimen...
  76. doi request reprint Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG)
    Ewa Lech-Maranda
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, Ciolkowskiego 2 Str, 93 510 Lodz, Poland
    Int J Infect Dis 14:e132-40. 2010
    ..The goal of this study was to determine the effect of this modification on the incidence and spectrum of infectious complications...
  77. ncbi request reprint Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells
    Piotr Smolewski
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital Lodz, Poland
    Leuk Lymphoma 46:87-100. 2005
    ..ALT and PNA or RTX trigger complementary changes in expression of proteins regulating cell propensity to undergo apoptosis, what provides molecular rationale for combining ALT with those agents...
  78. ncbi request reprint Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro
    Anna Szmigielska-Kaplon
    Department of Hematology, Medical University of Łódź, 93 513 Łódź, ul Pabianicka 62, Poland
    Eur J Haematol 68:370-5. 2002
    ..It failed however to point the best one to be combined with cladribine. We suggests that further clinical trials with such combinations are needed...
  79. ncbi request reprint Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG)
    A Wrzesien-Kus
    Department of Hematology, Medical University of Lodz, ul Pabianicka 62, 93 513 Lodz, Poland
    Ann Hematol 85:366-73. 2006
    ..We have shown that additional karyotype abnormalities did not influence the clinical characteristics of the patients; however, their influence on treatment results needs to be further assessed...
  80. ncbi request reprint Distribution and clinical significance of blood dendritic cells in children with juvenile idiopathic arthritis
    E Smolewska
    Department of Paediatric Cardiology, Medical University of Lodz, Sporna 36 50, 91 738 Lodz, Poland
    Ann Rheum Dis 67:762-8. 2008
    ..A role for dendritic cells (DC) in the development of adult rheumatoid arthritis has been suggested. To date, this problem has been poorly explored in juvenile idiopathic arthritis (JIA)...
  81. ncbi request reprint Skin lesions in chronic lymphocytic leukemia
    Ewa Robak
    Department of Dermatology and Venereology, Medical University of Lodz, Poland
    Leuk Lymphoma 48:855-65. 2007
    ..Other secondary lesions present as vasculitis, purpura, generalized pruritus, exfoliative erythroderma, and paraneoplastic pemphigus. An exaggerated reaction to an insect bite and insect bite-like reactions have been also observed...
  82. ncbi request reprint 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Leuk Lymphoma 34:151-7. 1999
    ..In conclusion, our results suggest that 2-CdA is also effective treatment for elderly patients with CLL. The drug toxicity is acceptable and seems to be similar for that observed in younger patients...
  83. ncbi request reprint Atypical chronic myelogenous leukemia following immunosuppressive therapy for severe aplastic anemia
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Leuk Lymphoma 35:193-9. 1999
    ..This case of atypical, secondary CML was refractory to treatment with interferon alpha and hydroxyurea...
  84. doi request reprint Circulating endothelial cells and angiogenic proteins in patients with systemic lupus erythematosus
    E Robak
    Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland
    Lupus 18:332-41. 2009
    ..These data may suggest that angiogenic process is involved in the pathogenesis of this disease...
  85. ncbi request reprint Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 510 Lodz, ul Ciołkowskiego 2, Poland
    Curr Med Chem 18:638-66. 2011
    ..This article reviews the various classes of AML targets and drugs that are under early phase clinical evaluation, especially those that are likely to enter clinical practice in the near future...
  86. ncbi request reprint Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients
    T Robak
    Department of Haematology, Medical University of Lodz, Institute of Haematology and Blood Transfusion, Warsaw, Poland
    Br J Haematol 108:357-68. 2000
    ..4%) pretreated and 74 (38.1%) untreated patients (P = 0.03), were the most frequent toxic effects. Our results indicate that 2-CdA is an effective, relatively well-tolerated drug, especially in previously untreated CLL...
  87. pmc Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, Poland
    Mediators Inflamm 8:277-86. 1999
    ..423; P<0.001). In addition, sIL-6R and OSM serum concentrations correlated also with CLL Rai stage. In conclusion, the serum level of IL-6, OSM and sIL-6R, but not LIF and sgp130, are useful indicators of CLL activity...
  88. ncbi request reprint Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Leuk Lymphoma 39:121-9. 2000
    ..5x10(9) G/l was 18.7 days and platelets>50x10(9)/l was 27.2 days. In conclusion, the CLAG regimen had significant antileukemic activity and acceptable toxicity as reinduction treatment in refractory or relapsed AML patients...
  89. ncbi request reprint Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Blood 96:2723-9. 2000
    ..The probability of overall survival calculated from Kaplan-Meier curves at 24 months was also similar for both groups (78% and 82%, respectively). (Blood. 2000;96:2723-2729)..
  90. ncbi request reprint Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Neoplasma 47:168-71. 2000
    ..These results may indicate that routine addition of corticosteroids to purine analogs in the treatment of lymphoid malignancies is not warranted...
  91. ncbi request reprint Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93 513 Lodz, ul Pabianicka 62, Poland
    Eur J Haematol 66:188-94. 2001
    ..Whether a combination of 2-CdA with cyclophosphamide and mitoxantrone would result in improved outcome as compared to 2-CdA alone, is being investigated in a prospective, randomised trial...
  92. ncbi request reprint Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland
    Leukemia 16:1015-27. 2002
    ..NA should be routinely used as second line treatment and possibly as first line therapy in younger patients, who are candidates for potentially curative treatment such as stem cell transplantation and/or monoclonal antibodies...
  93. ncbi request reprint Altered expression of nuclear non-histone protein (p44/46) in different stages of B-chronic lymphocytic leukemia
    Z M Kiliańska
    Department of Cytobiochemistry, S Banacha 12 16, University of Lodz, Poland
    Leuk Lymphoma 41:635-42. 2001
    ..The expression of this particular nuclear protein seems to correlate with the progression of the leukemia...
  94. ncbi request reprint Low-grade non-Hodgkin's lymphoma in a patient with systemic lupus erythematosus
    T Robak
    Department of Hematology Medical University of Lodz, Copernicus Memorial Hospital, Poland
    Leuk Lymphoma 41:659-67. 2001
    ..The SLE responded well to treatment with prednisone and the course of the LGNHL was stable and cytotoxic treatment was not required...
  95. ncbi request reprint Richter syndrome first manifesting as cutaneous B-cell lymphoma clonally distinct from primary B-cell chronic lymphocytic leukaemia
    E Robak
    Department of Dermatology, Medical University of Łódź, Łódź, Poland
    Br J Dermatol 153:833-7. 2005
    ..The patient was successfully treated with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) and adjuvant local radiotherapy...
  96. ncbi request reprint Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications
    T Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, 93 513 Lodz, Pabianicka 62, Poland
    Curr Cancer Drug Targets 5:421-44. 2005
    ..Three other compounds: clofarabine, nelarabine and immucillin-H are currently being evaluated clinically...
  97. ncbi request reprint Cladribine in the treatment of chronic lymphocytic leukemia
    T Robak
    Department of Hematology, Medical University of Lodz, Copernicus Hospital, Poland
    Leuk Lymphoma 40:551-64. 2001
    ..We suggest, that in patients with CLL, 2-CdA should be used as second line treatment rather than the first line therapy until the final results of ongoing randomized clinical trials are available...
  98. ncbi request reprint Expression of gene encoding P65 oncofetal protein in acute and chronic leukemias
    E Balcerczak
    Department of Pharmaceutical Biochemistry, Molecular Biology Laboratory Medical University, Lodz, 90 151 Poland
    Neoplasma 49:295-9. 2002
    ..No relationship between the expression of p65 gene and clinical stage of leukemia was observed. The lower percentage of positivity (presence of gene transcript) was seen in patients with ALL (42%) and AML (46%)...
  99. ncbi request reprint Richter's syndrome following cladribine therapy for chronic lymphocytic leukemia first manifested as pathologic fracture of the femur
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Leuk Lymphoma 42:789-96. 2001
    ..RS was first manifested as a pathologic fracture of the left femur. The LBCL was clonally distinct from the original CLL cells. The patient was successfully treated with CHOP and radiotherapy and obtained complete response of the LBCL...
  100. ncbi request reprint Influence of 2-chlorodeoxyadenosine (cladribine) on human erythrocytes
    A Marczak
    Department of Thermobiology, University of Łødź, Poland
    Int J Biochem Cell Biol 36:1645-54. 2004
    ..However, the higher concentrations of 2-CdA (about 5 microg/ml) can be also toxic to erythrocytes...
  101. ncbi request reprint 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland
    T Robak
    Department of Hematology, Medical University of Lodz, Poland
    Eur J Haematol 62:49-56. 1999
    ..The results of our study indicate that a 2-h infusion of 2-CdA in HCL patients is at least as effective as a 24-h infusion but more convenient to the patients, and may be given on an outpatient basis...